<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02155517</url>
  </required_header>
  <id_info>
    <org_study_id>019CBCEA032013</org_study_id>
    <nct_id>NCT02155517</nct_id>
  </id_info>
  <brief_title>Clinical Effect of Two Pharmacokinetics Model of Propofol</brief_title>
  <official_title>Phase 4: CLINICAL EVALUATION OF TWO PHARMACOKINETICS MODELS OF PROPOFOL IN HEALTHY PEOPLE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tiva Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tiva Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Actually, Schnider and Cortinez models represent pharmacokinetics models of propofol more&#xD;
      complete published until now. Schnider was derived from 24 healhty people, and including&#xD;
      other covariates in addition to weight, such as age, height and lean body mass though.&#xD;
      Schnider model should not be used in obese patients. Cortínez model was derived from 20 obese&#xD;
      patients. The differences between both models has been founded at the initial drug&#xD;
      distribution, that means V1 and the constant Ke0 ( pharmacokinetics factors that define the&#xD;
      plasma-effect equilibration time). We believe that Cortinez model also could be used in No&#xD;
      OBESE patients because is an allometric model, and one way to evaluate and to compare both&#xD;
      pharmacokinetics models is studying the temporary course of the effect.&#xD;
&#xD;
      The main objective of our study is to evaluate BIS and Cardiac Output values during&#xD;
      propofol-induced sedation using Schnider and Cortinez models in Target Controlled infusion in&#xD;
      non obese healthy volunteer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was approved by the ethics committee of the Avila Clinic. After informed consent,&#xD;
      10 volunteers aged 18-60 años, ASA I, Body mass Index &lt; 30 were included.&#xD;
&#xD;
      The patients fasted for 8h before the protocol and they will not receive premedication. After&#xD;
      arrival in the operating room, and insertion of 18-gauge intravenous cannulas placed into the&#xD;
      forearm, a Ringer's lactate solution will be initiated. Oxygen therapy at a rate of 5 litres&#xD;
      per minute will be administered in spontaneous ventilation. In case of hypoventilation&#xD;
      (saturation (SaO2) &lt;95% manual ventilation with a mask at 10 l/min of O2 will be&#xD;
      administered. All volunteer will be monitoring with EKG, Blood pressure, Pulse Oximetry,&#xD;
      Bispectral Index and Cardiac output.&#xD;
&#xD;
      Propofol will be administered using a commercially available target-controlled infusion with&#xD;
      an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical&#xD;
      System, Switzerland ). Each volunteer will be studied twice, that means which each subject&#xD;
      then acts as their own control.&#xD;
&#xD;
      The study will make in two stages:&#xD;
&#xD;
      STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen&#xD;
      (Schnider or Cortinez) using Target Controlled Infusion device, and the initial effect-site&#xD;
      target concentration of propofol will be 3 ug/ml for 20 minutes.&#xD;
&#xD;
      STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the&#xD;
      first model randomly chosen (Schnider or Cortinez) using Target Controlled Infusion devices,&#xD;
      and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.&#xD;
&#xD;
      Lost of consciousness will be evaluated by an independent observer using two different&#xD;
      criteria: OAA/S score &lt;2 (OAA/S2) corresponding to the absence of response to moderate&#xD;
      prodding and loss of eyelash reflex (LOER). Time to OAA/S2 and time to LOER will be measured&#xD;
      as well as corresponding brain and plasma concentrations of propofol. At the same time, BIS&#xD;
      and Cardiac output values will be recording.&#xD;
&#xD;
      After 20 minutes, the infusion will be stopped. Recovery of consciousness (ROC), which will&#xD;
      be assessed every 10s until patients wake up, and the values of Ce, BIS and Cardiac Output.&#xD;
&#xD;
      The electroencephalogram (EEG) activity will be monitored by BIS Quatro platform® electrodes&#xD;
      and a BIS VISTA™ 1.01 monitor Vista the bispectral index (Covidien, USA). The information&#xD;
      will be recording every 20 seconds The cardiac output will be measured using Monitor ICON ®&#xD;
      Electrical Cardiometric ™&#xD;
&#xD;
      Arterial blood pressure, heart rate, SaO2, respiratory frequency will be measured before to&#xD;
      start propofol infusion and then every 3 minutes until the end of trial. A decrease in&#xD;
      systolic arterial pressure ≥30 % of the basal value will be considered as hypotension, and&#xD;
      heart rate &lt;45 defined bradycardia.&#xD;
&#xD;
      STATISTICAL ANALYSIS This is a prospective, descriptive and comparative study. We will use&#xD;
      the Wilcoxon-Mann-Whitney nonparametric test applied for two independent samples&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation Levels</measure>
    <time_frame>During propofol infusion period</time_frame>
    <description>We will use Ramsey Sedation Scale to evaluate LOC at the beginning of the infusion and after 20 minutes we will evaluate the recovery of consciousness after the infusion is stopped.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bispectral index values</measure>
    <time_frame>During a propofol infusion period</time_frame>
    <description>We will use BIS monitor (BIS Vista, Covidien). The data will be collected in excel data sheet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics values</measure>
    <time_frame>During propofol infusion period</time_frame>
    <description>We will measure cardiac output using Monitor ICON ® Electrical Cardiometric ™, every 3 minutes.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Propofol Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol will be administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical System, Switzerland )..&#xD;
The study will make in two stages:&#xD;
STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.&#xD;
STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evaluation of propofol effect</intervention_name>
    <description>The study will make in two stages:&#xD;
STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.</description>
    <arm_group_label>Propofol Infusion</arm_group_label>
    <other_name>Propofol Induced sedation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evaluation of propofol effect</intervention_name>
    <description>STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.</description>
    <arm_group_label>Propofol Infusion</arm_group_label>
    <other_name>Propofol Induce sedation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA physical status I&#xD;
&#xD;
          -  Aged 18-60 years&#xD;
&#xD;
          -  Patients with Body mass Index &lt; 30.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Body mass Index &gt; 30.&#xD;
&#xD;
          -  Patients presenting psychiatric or neurological disorders , endocrine-metabolical&#xD;
             problems, respiratory and cardiac diseases, or with allergies problems.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Patients treated with psychotropic drugs, including alcohol, in the 48 hours prior.&#xD;
&#xD;
          -  Patients with previous history of anesthetics complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos R Ramirez, Dr</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Avila</name>
      <address>
        <city>Caracas</city>
        <state>Distrito Capital</state>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Venezuela</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2014</study_first_posted>
  <last_update_submitted>September 21, 2014</last_update_submitted>
  <last_update_submitted_qc>September 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tiva Group</investigator_affiliation>
    <investigator_full_name>Carolina Frederico</investigator_full_name>
    <investigator_title>Anestesiologo</investigator_title>
  </responsible_party>
  <keyword>TCI,Schnider Model, Cortinez Model, BIS, Cardiac Output.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

